Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBT: 2020-2025

Historic EBT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $216.3 million.

  • Apellis Pharmaceuticals' EBT rose 480.48% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year increase of 118.84%. This contributed to the annual value of -$196.7 million for FY2024, which is 62.64% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' EBT stood at $216.3 million, which was up 618.93% from -$41.7 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' EBT ranged from a high of $216.3 million in Q3 2025 and a low of -$219.2 million during Q2 2021.
  • For the 3-year period, Apellis Pharmaceuticals' EBT averaged around -$58.2 million, with its median value being -$66.3 million (2024).
  • In the last 5 years, Apellis Pharmaceuticals' EBT plummeted by 222.27% in 2021 and then soared by 480.48% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' EBT (Quarterly) stood at -$147.6 million in 2021, then fell by 13.47% to -$167.5 million in 2022, then skyrocketed by 47.96% to -$87.2 million in 2023, then skyrocketed by 58.62% to -$36.1 million in 2024, then surged by 480.48% to $216.3 million in 2025.
  • Its EBT stands at $216.3 million for Q3 2025, versus -$41.7 million for Q2 2025 and -$91.9 million for Q1 2025.